Feb 26, 2020 · In the KEYNOTE-522 trial, we evaluated the effect of neoadjuvant treatment on pathological complete response at the time of definitive surgery as well as the effect of both …

You are going to start on a chemotherapy treatment plan called KEYNOTE-522. 2 parts. Your provider may reverse the sequence in which the 2 parts are given. There are 2 parts to this …

Health care professionals may view findings from KEYNOTE-522, a clinical trial for patients with high-risk early-stage triple-negative breast cancer (TNBC).

Feb 16, 2024 · KEYNOTE-522 is the first prospective, phase III, randomized controlled study of pembrolizumab in patients with early-stage TNBC in the neoadjuvant and adjuvant settings.

Oct 1, 2024 · Background: In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab plus chemotherapy and then adjuvant pembrolizumab significantly improved pathological complete …

Nov 15, 2023 · In this secondary analysis of patients enrolled in KEYNOTE-522 in East and Southeast Asia, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant …

May 28, 2024 · KEYNOTE 522 is the fourth study of a KEYTRUDA-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-A18 in cervical cancer, …

Sep 15, 2024 · In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free …

Abstract Background. This study aimed to determine if the neoadjuvant (NAT) KEYNOTE-522 regimen was associated with higher rates of pathologic complete response (pCR), …

Oct 25, 2024 · For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago.